- Pfizer Inc.
- Nektar Therapeutics
- Alkermes PLC
- Eli Lilly & Co.
- Aradigm Corp.
- Novo Nordisk AS
- MannKind Corp.
- Amylin Pharmaceuticals Inc.
- Merck & Co. Inc.
- Medtronic PLC
- Johnson & Johnson
- Bayer AG
- Aerogen Ltd.
- Becton Dickinson & Co.
- GlaxoSmithKline PLC
- Biocon Ltd.
- Abbott Laboratories Inc.
- LifeScan Inc.
- Animas Corp.
- Inhale, Pfizer end inhaled insulin deal
- Alkermes develops inhalable insulin with Lilly; terminated
- Novo Nordisk, Aradigm end pulmonary insulin delivery deal
- Hoechst, Pfizer co-manufacture, -develop, -promote insulin
- Pfizer to buy Sanofi-Aventis' share of Exubera for $1.3bn
- AeroGen, BD develop inhalable insulin product
- Nobex, GSK sign $283mm oral insulin deal; cancelled
- Nektar Therapeutics buys Aerogen for $32mm in cash
- Abbott acquires Kos for $3.7bn in cash
- Bayer HealthCare, Nektar to develop inhalable Cipro
- Bayer to develop and sell Nektar's inhalable NKTR061
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. email@example.com.
All fields are required.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.